Singapore, September 4, 2007: Bharat Biotech International, an Indian biotech company launched BioHib, the first indigenously developed and manufactured Haemophilus Influenza type b (Hib) vaccine in India. It also launched its tetravalent combination vaccine, Comvac4-HB containing Diphtheria, Pertussis, Tetanus and Hepatitis B in one vaccine. These two new vaccines BioHib and Comvac4-HB, enable the deployment of a combination pentavalent vaccine in a single injection.   

According to the release, BioHib is a conjugate vaccine that has proven its safety and efficacy in multi-centric clinical trials. BioHib will be a safe and affordable vaccine that offers complete protection against Hib infections. It is a safe and efficacious vaccine developed with conjugation and manufacturing technologies developed at Bharat Biotech.

Dr Krishna M Ella, Chairman and Managing Director of Bharat Biotech said, “The launch of BioHib is a significant milestone for Bharat Biotech and more importantly for India, since all technologies were developed within India. BioHib has the ability to save the lives of millions of children worldwide at a very affordable price. The tetravalent and pentavalent vaccines give us the ability to protect children against multiple infectious diseases with a single injection. BioHib and Comvac4-HB are the latest offerings from Bharat Biotech in its commitment to develop safe and affordable vaccines for the developing world.” The scientific, manufacturing and product development teams at Bharat Biotech have completely developed all processes required to manufacture BioHib in-house at Bharat Biotech. It has made significant investments to the tune of several million of dollars over the past 4 years, into its R&D capabilities and its manufacturing facilities to enable the development and manufacture of BioHib.